{"id":"placebo-to-match-add-back","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it does not have a specific mechanism of action. It is used to provide a control group in clinical trials for the add-back therapy.","oneSentence":"This drug is a placebo used to match an add-back therapy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:47.241Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Matching placebo for add-back therapy"}]},"trialDetails":[{"nctId":"NCT04335591","phase":"PHASE3","title":"Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2020-03-05","conditions":"Endometriosis","enrollment":356},{"nctId":"NCT04372121","phase":"PHASE3","title":"Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain","status":"TERMINATED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2020-03-23","conditions":"Endometriosis","enrollment":30},{"nctId":"NCT03992846","phase":"PHASE3","title":"Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2019-06-13","conditions":"Endometriosis","enrollment":486},{"nctId":"NCT03986944","phase":"PHASE3","title":"A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain","status":"TERMINATED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2019-05-23","conditions":"Endometriosis","enrollment":85},{"nctId":"NCT02947750","phase":"PHASE2","title":"Neurovascular Transduction During Exercise in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Emory University","startDate":"2016-10","conditions":"Renal Insufficiency, Chronic","enrollment":150},{"nctId":"NCT03751124","phase":"PHASE3","title":"Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2018-10-16","conditions":"Uterine Leiomyoma, Uterine Fibroids","enrollment":229},{"nctId":"NCT03103087","phase":"PHASE3","title":"LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-06-14","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":382},{"nctId":"NCT03049735","phase":"PHASE3","title":"LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-04-26","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":388},{"nctId":"NCT03070899","phase":"PHASE3","title":"Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"ObsEva SA","startDate":"2017-04-20","conditions":"Uterine Fibroids, Heavy Menstrual Bleeding","enrollment":526},{"nctId":"NCT03070951","phase":"PHASE3","title":"Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"ObsEva SA","startDate":"2017-05-23","conditions":"Uterine Fibroids, Heavy Menstrual Bleeding","enrollment":511},{"nctId":"NCT02042196","phase":"EARLY_PHASE1","title":"Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-12","conditions":"Menopause, Aging","enrollment":100},{"nctId":"NCT02213029","phase":"PHASE1","title":"A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2014-08-28","conditions":"Embryo Transfer","enrollment":33},{"nctId":"NCT00973024","phase":"PHASE2","title":"A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2009-09","conditions":"Low Back Pain, Low Back Pain, Recurrent","enrollment":389}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to match Add-back","genericName":"Placebo to match Add-back","companyName":"ObsEva SA","companyId":"obseva-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug is a placebo used to match an add-back therapy. Used for Matching placebo for add-back therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}